acute myeloid leukemia. Acute myeloblastic leukemia
Conditions
Interventions
All patients are included in the only intervention arm of the study. Patients in the intervention arm will receive two doses of in-vitro expanded NK cells at the 6 and 12 days after transplantation un
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Age 18 years old or more Recipients of allogeneic Stem Cell Transplantation for high-risk Acute Myeloid Leukemia by ELN classification Recipients of allogeneic Stem Cell Transplantation from matched or mismatched donors. MRD = 5% after the first Induction or MRD = 0.1% after the second Induction or MRD = 0.01% before transplantation Normal organ function
Exclusion criteria
Exclusion criteria: Second allogeneic Stem Cell Transplantation Active or uncontrolled infection Acute graft versus host disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Patients With Grades 3-5 of Natural Killer cell infusion-related Adverse Events. Timepoint: Daily during the first seven days after the injection. Method of measurement: History, Physical exam, and lab test.;Relapse Incidence. Timepoint: one year after infusion. Method of measurement: Bone marrow aspiration and biopsy. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Barkhordar
Tehran University of Medical Sciences
Outcome results
None listed